title: Successful treatment of Kaposiform hemangioendothelioma with everolimus.
abstract: There is currently no consensus on the second-line management of Kaposiform hemangioendothelioma (KHE) that was resistant to prednisolone and vincristine. We described an eight-year-old male with KHE in the right femur that was resistant to prednisolone, vincristine and propranolol. Everolimus, an inhibitor of mammalian target of rapamycin (mTOR) at the dosage of 0.1 mg/kg/day, successfully decreased the tumor size and controlled the symptoms. Everolimus should be further studied as an alternative agent to sirolimus in the management of KHE.
authors.affiliation: Children's Cancer Center, National Center for Child Health and Development, Setagaya, Tokyo, Japan.
authors.forename: Teruaki
authors.initials: T
authors.lastname: Uno
authors.forename: Shuichi
authors.initials: S
authors.lastname: Ito
authors.forename: Atsuko
authors.initials: A
authors.lastname: Nakazawa
authors.forename: Osamu
authors.initials: O
authors.lastname: Miyazaki
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Mori
authors.forename: Keita
authors.initials: K
authors.lastname: Terashima
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D002648:Child; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D000068338:Everolimus; D006390:Hemangioendothelioma / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D059885:Kasabach-Merritt Syndrome / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D011239:Prednisolone / Q000008:administration & dosage; D011433:Propranolol / Q000008:administration & dosage; D012514:Sarcoma, Kaposi / Q000188:drug therapy* / Q000473:pathology; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives*; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D007166:Immunosuppressive Agents; D014750:Vincristine; D000068338:Everolimus; D011239:Prednisolone; D011433:Propranolol; D020123:Sirolimus
keywords: Kasabach-Merritt phenomenon; mTOR; rapamycin; sirolimus; vascular tumor